Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib

Abstract

Bortezomib, in combination with dexamethasone (VD) or with the addition of cyclophosphamide (VCD), is highly effective in patients with amyloid light-chain (AL) amyloidosis. Currently, VCD is considered as a primary regimen for patients with AL, but it is not clear whether the addition of cyclophosphamide to VD further and significantly improves efficacy… (More)
DOI: 10.1038/bcj.2017.47

Topics

4 Figures and Tables

Cite this paper

@inproceedings{Kastritis2017AdditionOC, title={Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib}, author={Efstathios Kastritis and Maria Roussou Magdalini Migkou Maria Gavriatopoulou and Maria Roussou and Dimitris F Fotiou and Dimitris C Ziogas and Magdalini Migkou and Evaggelos Eleutherakis-Papaiakovou and Ioannis Panagiotidis and Nikos Kanellias and Erasmia Psimenou and Ekaterini Papadopoulou and Constandinos A Pamboucas and Efstathios Manios and Hariklia Gakiopoulou and Argyrios S Ntalianis and Anna Tasidou and Stamatina Giannouli and Evangelos Terpos and Meletios Athanasios Dimopoulos}, booktitle={Blood cancer journal}, year={2017} }